A Novel Mechanism for Sarcopenia in Chronic Kidney Disease
慢性肾脏病肌肉减少症的新机制
基本信息
- 批准号:10265352
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-01 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AMP DeaminaseAdenosine MonophosphateAffectAgingAmericanAnimalsAutomobile DrivingBiological MarkersBiological ProcessBody CompositionCachexiaCatabolismCell physiologyChronic Kidney FailureCodeComplicationDataDeaminaseDiabetes MellitusDietDiseaseElderlyEnzymesExercise ToleranceFemaleGDF8 geneGeneral PopulationGenerationsGrowthHealthImpairmentIndividualInflammationInsulin ResistanceInternational Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)IntramuscularKidneyKidney DiseasesKnockout MiceLaboratoriesLeadMediatingMetabolic acidosisMetabolic syndromeModelingMolecularMorbidity - disease rateMusMuscleMuscular AtrophyObesityOxidative StressPathogenesisPathway interactionsPhenotypePlayPopulationPrevalenceProtein IsoformsProtein KinaseProteinsRenal functionRiskRoleSecondary toSkeletal MuscleSystemTestingTherapeuticUbiquitinUric AcidVeteransVeterans Health Administrationaging populationcostcost estimateenergy balancefallsfrailtyfunctional declinefunctional lossimprovedinnovationinorganic phosphateinsightinsulin sensitivityinterestmalemilitary veteranmortalitymouse modelmuscle formnovelnovel strategiesnutritionoverexpressionphysical inactivitypreservationprophylacticrenal damagesarcopeniauptakewasting
项目摘要
Sarcopenia (muscle wasting) is a crippling condition that affects 25% of the aging population and even a
greater percentage of subjects with chronic kidney disease (CKD), and is disproportionately high among
veterans. Now recognized as a disease entity with its own ICD-10 code, it is associated with increased
mortality and carries an annual US cost estimated to be more than 11.8 billion dollars and yet there is very little
known of its pathogenesis or treatment. Sarcopenia is common in the aging population, especially those with
obesity and diabetes. However, one population that commonly suffers from sarcopenia are those individuals
suffering from chronic kidney disease, where both young and old are affected. It is now recognized that the
disease does not result simply from poor nutrition and physical inactivity, but is often driven by inflammation
and oxidative stress that can progress to protein-energy wasting, frailty and cachexia. The biological processes
that are involved include effects of metabolic acidosis to stimulate protein catabolism from activation of the
ubiquitin system, overexpression of myostatin that inhibits muscle growth, effects of insulin resistance, and
other mechanisms. While much has been learned about these basic cellular processes involved in sarcopenia,
here we present a novel hypothesis suggesting that the enzyme AMP deaminase 1 (AMPD1) may have a
central role in causing sarcopenia by both regulating intracellular energy (ATP) levels and driving inflammation
and oxidative stress. Using a model of chronic kidney disease in mice (remnant kidney model on a high protein
diet), we have documented that the animals develop sarcopenia and in preliminary studies that sarcopenia
does not occur in mice lacking AMPD1 with equivalent kidney damage. Here we will extend our studies to
determine the effect of blocking AMPD1 in both male and female and both young and old mice with kidney
disease, in association with extensive phenotyping including exercise tolerance, and studies of energy balance
and body composition. Second we will explore the mechanisms by which AMPD1 activation causes
inflammation, focusing on the role of uric acid and inhibition of AMP activated protein kinase. Finally, we will
explore the basis underlying the activation of AMPD1 in chronic kidney disease, with an emphasis on the role
of intracellular phosphate depletion and insulin resistance. If we identify activation of AMPD1 as a cause of
sarcopenia and show that it is driven by insulin resistance, intracellular phosphate depletion and uric acid
generation, we will not only identify a mechanism driving a severe complication of chronic kidney disease but
also a potential way to intervene both prophylactically and therapeutically. Such a discovery would be of great
help to all individuals with chronic kidney disease, and would have a big impact on Veterans and the Veteran
Health Administration.
骨质疏松症(肌肉萎缩)是一种严重的疾病,影响25%的老龄化人口,甚至
患有慢性肾脏疾病(CKD)的受试者比例更高,在
退伍军人。现在被认为是一种拥有自己的ICD-10代码的疾病实体,它与
死亡率和每年在美国造成的损失估计超过118亿美元,然而
已知其发病机制或治疗方法。骨质疏松症在老龄化人口中很常见,特别是那些患有
肥胖和糖尿病。然而,通常患有骨质疏松症的人群就是这些个体。
患有慢性肾脏疾病,年轻人和老年人都会受到影响。现在人们认识到,
疾病不仅仅是营养不良和缺乏运动所致,而往往是由炎症引起的。
氧化应激可导致蛋白质能量浪费、虚弱和恶病质。生物过程
所涉及的包括代谢性酸中毒的影响,以刺激蛋白质分解代谢激活
泛素系统,抑制肌肉生长的肌肉生长抑制素过表达,胰岛素抵抗的影响,以及
其他机制。虽然关于这些与石棺减少症有关的基本细胞过程已经了解了很多,
在这里,我们提出了一个新的假说,认为AMP脱氨酶1(AMPD1)可能具有
通过调节细胞内能量(ATP)水平和促进炎症,在导致骨质疏松症中发挥核心作用
和氧化应激。采用小鼠慢性肾脏病模型(高蛋白残余肾模型
饮食),我们已经记录了这些动物会出现石棺减少症,并且在初步研究中,石棺减少症
在缺乏AMPD1并有同等肾脏损害的小鼠中不会发生这种情况。在这里,我们将把我们的研究扩展到
阻断AMPD1对雄性和雌性及幼年和老年小鼠肾脏的影响
疾病,与广泛的表型相关,包括运动耐量和能量平衡研究
和身体成分。第二,我们将探索AMPD1激活导致
炎症,重点是尿酸的作用和抑制AMP活化的蛋白激酶。最后,我们会
探讨AMPD1在慢性肾脏疾病中激活的基础,重点是其作用
细胞内磷酸盐耗竭和胰岛素抵抗。如果我们确定AMPD1的激活是导致
并表明它是由胰岛素抵抗、细胞内磷酸盐耗竭和尿酸引起的
一代,我们不仅将确定导致慢性肾脏疾病严重并发症的机制,而且
也是一种预防和治疗干预的潜在方法。这样的发现将是伟大的
帮助所有患有慢性肾脏疾病的人,并将对退伍军人和退伍军人产生重大影响
卫生署。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Joseph Johnson其他文献
Richard Joseph Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Joseph Johnson', 18)}}的其他基金
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
- 批准号:
10221502 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
- 批准号:
10441315 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
- 批准号:
10659119 - 财政年份:2019
- 资助金额:
-- - 项目类别:
A Novel Mechanism for Sarcopenia in Chronic Kidney Disease
慢性肾脏病肌肉减少症的新机制
- 批准号:
10454871 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Fructokinase Inhibitors for the Treatment of Alcohol Use Disorder
用于治疗酒精使用障碍的果糖激酶抑制剂
- 批准号:
10022080 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Dietary Salt has an Unrecognized Role in Modulating Energy Intake and Metabolic Syndrome
膳食盐在调节能量摄入和代谢综合征方面的作用尚未被认识
- 批准号:
9114329 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity
果糖激酶抑制治疗肥胖的科学价值和可行性
- 批准号:
9464351 - 财政年份:2015
- 资助金额:
-- - 项目类别:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
果糖激酶与非糖尿病和衰老相关的慢性肾脏病
- 批准号:
9275427 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
果糖激酶与非糖尿病和衰老相关的慢性肾脏病
- 批准号:
8966551 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Fructokinase and Nondiabetic and Aging-Associated Chronic Kidney Disease
果糖激酶与非糖尿病和衰老相关的慢性肾脏病
- 批准号:
9789159 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似海外基金
Late-Stage Functionalisation of Cyclic Guanosine Monophosphate - Adenosine Monophosphate
环单磷酸鸟苷-单磷酸腺苷的后期功能化
- 批准号:
2751533 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Studentship
The Role of Chronic Pharmacological Adenosine Monophosphate-Activated Protein Kinase Activation at the Neuromuscular Junction
慢性药理学单磷酸腺苷激活蛋白激酶激活在神经肌肉接头处的作用
- 批准号:
575833-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Targeting adenosine monophosphate activated protein kinase (AMPK) to reduce cocaine relapse
靶向单磷酸腺苷激活蛋白激酶 (AMPK) 减少可卡因复吸
- 批准号:
10593045 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Targeting adenosine monophosphate activated protein kinase (AMPK) to reduce cocaine relapse
靶向单磷酸腺苷激活蛋白激酶 (AMPK) 减少可卡因复吸
- 批准号:
10303255 - 财政年份:2022
- 资助金额:
-- - 项目类别:
The regulation of electrical coupling between neuroendocrine cells by cyclic adenosine monophosphate and protein kinase A
环磷酸腺苷与蛋白激酶A对神经内分泌细胞电耦合的调节
- 批准号:
565217-2021 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Dissecting the Molecular Mechanisms of the Histone Acetyltransferase/Cyclic Adenosine Monophosphate Binding Protein Interactome Using Protein-Observed Fluorine NMR
使用蛋白质观察的氟 NMR 剖析组蛋白乙酰转移酶/环单磷酸腺苷结合蛋白相互作用组的分子机制
- 批准号:
1904071 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Standard Grant
Osmotic stress regulation and the role of cyclic di-adenosine monophosphate (c-di-AMP) in Staphylococcus aureus
金黄色葡萄球菌的渗透应激调节和环二腺苷单磷酸 (c-di-AMP) 的作用
- 批准号:
318765828 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Research Fellowships
Novel mechanisms controlling signaling by adenosine monophosphate-activated protein kinase, central regulator of energy homeostasis
通过单磷酸腺苷激活蛋白激酶控制信号传导的新机制,能量稳态的中央调节器
- 批准号:
FT130100988 - 财政年份:2014
- 资助金额:
-- - 项目类别:
ARC Future Fellowships
The roles of cyclic adenosine monophosphate (cAMP) in suppressive functions of regulatory T cells
环磷酸腺苷 (cAMP) 在调节性 T 细胞抑制功能中的作用
- 批准号:
25893115 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Research Activity Start-up
Molecular mechanisms of cyclic Adenosine Monophosphate (AMP) induced apoptosis
环磷酸腺苷(AMP)诱导细胞凋亡的分子机制
- 批准号:
DP110100417 - 财政年份:2011
- 资助金额:
-- - 项目类别:
Discovery Projects














{{item.name}}会员




